Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -1.97% 7.45 7.20 7.70 7.60 7.45 7.60 154,860 12:32:54
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -2.1 - 20

Evgen Pharma Share Discussion Threads

Showing 7951 to 7971 of 8400 messages
Chat Pages: Latest  324  323  322  321  320  319  318  317  316  315  314  313  Older
DateSubjectAuthorDiscuss
28/3/2021
11:41
From his December interview with Proactive... “We create compelling data sets for larger companies to take forward. That is our strategy that we have redefined since I joined essentially...” Note the use of “redefined”. In fact, just watch the video again. Everything is there to explain the business model and the use of commercial partnerships, going FORWARD. In this context, The past is the past. httPs://www.stocktube.com/companies/news/936683/evgen-pharma-have--many-shots-at-goal--solving-unmet-needs-in-the-pharmaceutical-industry-936683.html
bumpa33
28/3/2021
11:32
Don't forget a lot of vct/EIS so their cost price is halved !! I would also be a buyer at 4p !!
nico115
28/3/2021
11:31
I'm not bearish here For me it's a punt If directors were to buy in meaningfully here this would be an outstanding buy Until that point there are much better calculated risks in the market like STX where directors have put their money where their mouths are and has passed all trials !!
nico115
28/3/2021
11:19
Don't forget the rest of my post nico.. However, you can't ignore the fact that EVG is well backed by quality institutional investors, especially so in the recent placing. It gives plenty of reassurance that there isn't 'something up' that these guys saw fit to invest millions earlier this month: Major shareholder Number of shares Percentage holding AXA Framlington 23,848,884 8.7% Octopus Investments 21,875,000 8.0% SPARK Impact 16,186,446 5.9% Seneca Investment Managers 14,932,071 5.4% Chelverton Asset Management 12,500,000 4.5% RAB Capital 8,750,000 3.2% Newlands Capital 8,314,815 3.0%
on target
28/3/2021
11:10
I don’t think in the past the company has had the financial clout, or more critically the leadership, to do anything other than partner with academic bodies in seemingly random indications adding up to a rather scatter gun and lightweight approach. We now hopefully have the leadership, the cash and a plan to pursue partnerships with commercial entities - that’s how it looks to me, whether they can do it is another matter. Further, Jones has made a point of referencing that they’ll be concentrating on areas with little competition, hence making the process of getting a drug to market (and critically, partners) somewhat easier - especially in diseases with a high unmet therapeutic need, Gliobastoma/Glioma being a perfect case in point.
bumpa33
28/3/2021
10:59
On target "The directors' very modest holdings and their tiny top-ups in the recent placing are annoying, and I'd very much like them to put some decent money in. "Exactly my thoughts Target Appreciate your honesty Agreed it's a worry
nico115
28/3/2021
10:31
I would rather follow the directors I'm long here but if Helen doesn't buy I'm out If you think buying 3k shares shoes confidence you need to see a doctor ASAP Tell me why directors refuse to buy when we are trading at such a low EV ?Maybe we would be better to use the cash as a cash shell and ask Vin M to join the board?I'm v nervous
nico115
27/3/2021
22:29
Oh yes amaretto who deramps STX where directors have invested millions of pounds ..currently 33p will be over 100pAnd amaretto Ramps evg where directors bought 300 quid of stock ..will be 2pI can't wait to dump my evg The directors are a disgrace
nico115
27/3/2021
21:27
I used to hold some Evgen shares in the past. My two cents.... the company tends to bite a little more than it can chew. The indications it has focused on:- breast cancer, COVID, SAH (in past)... these indications need lots of $$$$. Not easy to get a drug approved in these disease areas, even for big Pharma. Look at Reata with their NRF-2 inhibitors...being developed successfully for orphan diseases. I don’t think Evgen has had very experienced medical/scientific leadership, with knowledge to bring these drug assets across the line. In the recent fund raise, I would have targeted £20 million. Anyway, my humble opinion.
diamondstar1
27/3/2021
21:16
Some decent names on the share register there & certainly been some churn at the ii level over the last 12 months. Let’s hope that transition phase is ending and similarly the transition in business model will now start to bear fruit.
bumpa33
27/3/2021
21:09
httPs://www.wsj.com/articles/covid-19-variant-rages-in-brazil-posing-global-risk-11616845889?redirect=amp#click=hxxps://t.co/Af1EIwanBo makes for chastening reading...
bumpa33
27/3/2021
19:36
Succinct and to the point Amaretto
bocker01
27/3/2021
18:19
Where did that short thread come from? Are they nuts?
notknowing
27/3/2021
18:08
Thx I'm a seller now Unless Helen buys Let's see
nico115
27/3/2021
17:35
Thanks OT.
the millipede
27/3/2021
15:17
He still hasn't resurfaced as far as I know,but good luck to him regardless and I think he ended up with over 4.5m shares and so no doubt would be prudent if he had kept a few for Evgen's "next stage" and true and substantial value. As far as the new new high quality investors and existing Major shareholders are concerned who participated in the £10m placing, I wouldn't be surprised if they had been given access to some of the data on the breast cancer programme and other targets yet to be made public as well as the compelling data on glioma/glioblastoma, we also know that Octopus has a strong connection with Jim Mellon which could have had some sway....anyways, looking forward to Q2 with great excitement and anticipation to see what Huw has to report. Gla :')
moneymunch
27/3/2021
14:52
This is what he posted on his linkedin account at the time: "Taking time out Hi all - I have been inundated with calls and messages since yesterday's announcement, so I thought I would make a short post on my personal Linked-In account. Deciding to leave Evgen was a tough call, but one that I made in the best interests of the shareholders. The share price has been suppressed for a while and does not reflect the true and substantial value in the business. What is needed now is fresh vision and new energy to take it to the next stage. The Company remains a great business and I will continue to support them as a long-term shareholder. I intend to take a short break now to recharge and will resurface in due course. Thank you to all those that have sent kind messages at this time of change."
on target
27/3/2021
14:26
The directors' very modest holdings and their tiny top-ups in the recent placing are annoying, and I'd also like them to put some decent money in. However, you can't ignore the fact that EVG is well backed by quality institutional investors, especially so in the recent placing. It gives plenty of reassurance that there isn't 'something up' that these guys saw fit to invest millions earlier this month: Major shareholder Number of shares Percentage holding AXA Framlington 23,848,884 8.7% Octopus Investments 21,875,000 8.0% SPARK Impact 16,186,446 5.9% Seneca Investment Managers 14,932,071 5.4% Chelverton Asset Management 12,500,000 4.5% RAB Capital 8,750,000 3.2% Newlands Capital 8,314,815 3.0% These guys aren't bucket shops and neither are they mug punters.
on target
27/3/2021
13:53
And if the directors were onlyLookingFor 3 to 5m why did they raise 10m ? Maybe they aren't confident of decent trial results ?I bought a chunk at 8p but now seriouslyConsidering dumping them Director buys or lack of them worries me
nico115
27/3/2021
13:29
The former CEO had quite a lot of shares, but he might have sold. Anyone have any idea why he left? (Beyond what was written in the RNS.)
the millipede
27/3/2021
13:05
The directors' very modest holdings and their tiny top-ups in the recent placing are annoying, and I'd very much like them to put some decent money in. However, you can't ignore the fact that EVG is well backed by quality institutional investors, especially in the recent placing. It gives plenty of reassurance that there isn't 'something up' that these guys saw fit to invest millions earlier this month: Major shareholder Number of shares Percentage holding AXA Framlington 23,848,884 8.7% Octopus Investments 21,875,000 8.0% SPARK Impact 16,186,446 5.9% Seneca Investment Managers 14,932,071 5.4% Chelverton Asset Management 12,500,000 4.5% RAB Capital 8,750,000 3.2% Newlands Capital 8,314,815 3.0%
on target
Chat Pages: Latest  324  323  322  321  320  319  318  317  316  315  314  313  Older
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210515 18:06:05